Drug intelligence / Profile preview

nitroglycerin + lidocaine

Development stage: Unknown
Modality: Small Molecules
Administration: Topical, Rectal, Intravenous

Overview

A combination medication consisting of nitroglycerin and lidocaine. Nitroglycerin acts as a vasodilator by relaxing blood vessels, increasing blood flow and oxygen supply to tissues[4][6]. When applied topically, it causes local vasodilation without significantly affecting systemic blood pressure[2][7]. Lidocaine, on the other hand, acts as a local anesthetic, providing pain relief by temporarily numbing the affected area[3]. This combination is used for various applications including radial artery dilation prior to cardiac catheterization, treatment of anal fissures, and enhancement of intravenous regional anesthesia.

Brand names: Rectiv

Targets

NaV (Voltage-gated sodium channels)sGC (Soluble Guanylyl Cyclase)

Beyond the preview

Go deeper on nitroglycerin + lidocaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nitroglycerin + lidocaine.

Explore the full profile